DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.